Literature DB >> 6527251

Pharmacokinetics of probucol in male rats.

J F Heeg, M F Hiser, D K Satonin, J Q Rose.   

Abstract

The bioavailability and pharmacokinetic behavior of 10 mg/kg of [14C]probucol in an oil-water emulsion was determined after oral and intravenous administration to rats. The bioavailability of the oral formulation was approximately 6%. For the first 12-h interval after the intravenous bolus, plasma probucol concentrations increased after an initial decrease. This effect may be attributed to the formulation or precipitation of the drug in the vasculature. The terminal plasma half-life was 6 d. By 7 d, 45 and 4.65% of the labeled intravenous bolus was excreted in the feces and in the urine, respectively. Although most of the labeled dose was excreted in the bile, any enterohepatic recirculation that did occur did not contribute to the atypical plasma concentration versus time profile. The tissue distribution of the label and elimination rates in the bile differed between the two routes of administration. Either the total body burden, precipitation of the drug, or the emulsion vehicle may be responsible for the nonlinear distribution and clearance of the intravenous dose.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6527251     DOI: 10.1002/jps.2600731225

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats.

Authors:  Mari Jiko; Ikuko Yano; Hiroko Wakasugi; Hideyuki Saito; Ken-ichi Inui
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

Review 2.  Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.

Authors:  M M Buckley; K L Goa; A H Price; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

3.  Directed self-assembled nanoparticles of probucol improve oral delivery: fabrication, performance and correlation.

Authors:  Zhiwen Zhang; Shijun Jiang; Zeying Liu; Baohua Niu; Wangwen Gu; Yaping Li; Jingbin Cui
Journal:  Pharm Res       Date:  2014-03-04       Impact factor: 4.200

4.  An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer.

Authors:  Armin Mooranian; Rebecca Negrulj; Nigel Chen-Tan; Gerald F Watts; Frank Arfuso; Hani Al-Salami
Journal:  Drug Des Devel Ther       Date:  2014-09-29       Impact factor: 4.162

5.  Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol.

Authors:  Armin Mooranian; Rebecca Negrulj; Nigel Chen-Tan; Hesham S Al-Sallami; Zhongxiang Fang; T K Mukkur; Momir Mikov; Svetlana Golocorbin-Kon; Marc Fakhoury; Gerald F Watts; Vance Matthews; Frank Arfuso; Hani Al-Salami
Journal:  Drug Des Devel Ther       Date:  2014-09-09       Impact factor: 4.162

6.  Enhanced Antioxidant Effects of the Anti-Inflammatory Compound Probucol When Released from Mesoporous Silica Particles.

Authors:  Michael Lau; Benjamin Sealy; Valery Combes; Marco Morsch; Alfonso E Garcia-Bennett
Journal:  Pharmaceutics       Date:  2022-02-24       Impact factor: 6.525

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.